FDA Updates Fluoroquinolone Warnings for Mental Health, Hypoglycemia Risks

Officials with the FDA are requiring safety label updates for fluoroquinolone antibiotics due to risks of mental health adverse effects and blood sugar disturbances, according to a press release
 
The FDA stated that all fluoroquinolone antibiotics already included a range of mental health adverse effects described in the Warnings and Precautions section of the drug labeling, but have differed by individual drug.
 
Now, the FDA is requiring mental health adverse effects to be listed separately from the other central nervous system adverse effects, and be consistent across the labeling of all fluoroquinolone antibiotics. The mental health adverse effects to be included in the updated labeling are disturbances in attention, disorientation, agitation, nervousness, memory impairment, and delirium.
 
The updates apply to the drug labels and the patient medication guides for the entire class of fluoroquinolones, which affect only the fluoroquinolone formulations taken by mouth or given by injection.
 
According to an FDA drug safety communication, the new label changes “will make the mental health side effects more prominent and more consistent across the systemic fluoroquinolone drug class.”
 
FDA-approved fluoroquinolones include levofloxacin (Levaquin), ciprofloxacin (Cipro), ciprofloxacin extended-release tablets, moxifloxacin (Avelox), ofloxacin, gemifloxacin (Factive), and delafloxacin (Baxdela).
 
Additionally, the labeling must also be updated to include risks related to hypoglycemia. Based on a previous review that found instances of hypoglycemic coma in users of fluoroquinolones, the FDA is requiring that the Blood Glucose Disturbances subsection of the labeling be updated to explicitly reflect the potential risk of coma with hypoglycemia.
 
The FDA urges health care professionals to be aware of the potential risk of hypoglycemia sometimes resulting in coma, which can occur in elderly patients and those with diabetes taking an oral hypoglycemic medicine or insulin.
 
References
 
FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions [news release]. FDA’s website. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm612995.htm?utm_campaign=07102018_PR_FDA%20updates%20warnings%20for%20fluoroquinolone%20risks&utm_medium=email&utm_source=Eloqua. Accessed July 10, 2018.
 

FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes [safety announcement]. FDA’s website. https://www.fda.gov/Drugs/DrugSafety/ucm611032.htm. Accessed July 10, 2018. 

 
 
 


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

NYU Langone Health discusses the challenges and benefits involved in starting or expanding a health system’s specialty pharmacy.
A new trend is emerging as health system–based specialty pharmacies become a staple in the industry.
Top news of the day from across the health care landscape.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$